IL6 and cancer: For instance, Nab-paclitaxel treatment increases CXCL-10 expression in pancreatic cancer cells, leading to lower IL-6 secretion by CAFs subsequently impairing migration and invasive capabilities of cancer cells (Feng et al., 2018).